Related Experiment Videos
[Modern drug development by molecular- and cell-biological methods].
1Technische Universität München und GenPharmTox BioTech AG, D-Martinsried. doehmer@lrz.tum.de
ALTEX
|March 15, 2001
Summary
Genetically modified V79 cells, forming the V79 Cell Battery, enable early preclinical drug metabolism testing. This novel approach bypasses animal testing limitations for human relevance in drug development.
Area of Science:
- Biotechnology
- Pharmacology
- Toxicology
Context:
- GenPharmTox BioTech AG has developed genetically modified V79 cells.
- These cells are engineered to mimic human drug metabolism and chemical activation.
- The V79 Cell Battery is a novel in vitro system.
Purpose:
- To provide an accurate preclinical model for drug metabolism.
- To assess metabolic activation of chemicals relevant to human drug development.
- To circumvent limitations associated with animal testing in drug evaluation.
Summary:
- The V79 Cell Battery comprises genetically modified V79 cells designed for human metabolism functions.
- This system allows for early-stage drug metabolism and chemical activation testing during preclinical development.
- It offers direct relevance for clinical drug testing by overcoming animal extrapolation issues.
Impact:
- Enables more reliable early-stage drug development decisions.
- Reduces reliance on animal testing for metabolic profiling.
- Improves the predictive accuracy of preclinical drug metabolism data for human outcomes.